The president and CEO of NeuroPace Inc. (NPCE), Mike Favet, says that the commercial-stage medical device company created a RNS System for drug-resistant epilepsy. The stock began publicly trading today with shares opening for trade at $23.25 per share.
Market On Close
22 Apr 2021
SHARE
The Watch List
22 Feb 2022
The Watch List
01 Mar 2022
The Watch List
10 Feb 2022
Market On Close
03 Feb 2022
The Watch List
20 Apr 2022
Trading 360
09 Feb 2022